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2018 UK national guideline for the management of infection with Mycoplasma 
genitalium 
 
Suneeta Soni, Paddy Horner, Michael Rayment, Nicolas Pinto-Sander, Nadia Naous, Andy Parkhouse, 
Darren Bancroft, Carl Patterson, Helen Fifer 
 
Introduction  
This is the first British Association of Sexual Health and HIV (BASHH) guideline for the diagnosis and 
management of Mycoplasma genitalium in people aged 16 years and older. The guideline is primarily 
aimed at level 3 sexually transmitted infection (STI) management services within the UK although it could 
also serve as a reference guide for STI services at other levels.  
Whilst the guideline sets out recommendations for best practice according to current evidence, it is 
acknowledged that not all clinics will have access to M. genitalium testing at the time of guideline 
publication. The objective of this guideline is therefore also to assist clinics and laboratories in making 
the case for funding towards M. genitalium testing by underlining the importance of testing in relevant 
populations.  
Editorial independence 
This guideline was commissioned and edited by the Clinical Effectiveness Group (CEG) of BASHH, 
which also provided funding for a literature search. No other or external funding was obtained. 
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Rigour of development 
This guideline was produced according to specifications made in the CEG’s document ‘2015 






The writing group determined PICO (Patient, Intervention, Comparison, Outcome) questions which 
formed the basis for the literature search, and are listed in Appendix 1. 
A search was conducted using Medline, Embase, the Cochrane library and NHS Evidence. The search 
heading was kept broad (“genitalium”) to include all the guideline questions. Only publications in the 
English language were considered. Age, country and study design limits were included in the PICO 
criteria, except that studies from Japan were considered for questions 8, 9 and 10 because it was felt 
that evidence in these studies, particularly with respect to resistance and treatment issues, would 
contribute significantly to and inform the guideline (see Appendix 1). ‘Grey literature’ included 
conference abstracts from IUSTI, BASHH, BHIVA, ICAAC, ASHM, ECCMID in the last three years. The 
writing group used a modified GRADE system for assessing evidence and formulate recommendations. 
 
Equality impact assessment  
An assessment of the guideline recommendations was made according to the principles of the NICE 
equality policy (Appendix 2).  
 
 
Stakeholder involvement, piloting and feedback.  
The draft guideline recommendations were presented at the joint British HIV Association and BASHH 
annual conference 2018. The draft guideline was appraised by the CEG using the AGREE instrument, 
posted on the BASHH website for a consultation period of 2 months and piloted in a sample of clinics. 
In response to the consultation, suitable amendments were made to the guideline and the final draft 
was submitted to the CEG. The patient information leaflet (PIL) was reviewed by the CEG, BASHH 
patient and public panel and also piloted in a sample of clinics and comments were reviewed and 
incorporated where appropriate.  
The writing group consisted of genitourinary medicine physicians with experience in managing 
Mycoplasma genitalium (SS, MR, NPS, PH), a consultant microbiologist (HF), a pharmacist (NN), a 
sexual health advisor (AP) and two patient representatives (DB, CP). 
The guideline will be updated every five years according to the BASHH CEG guideline framework. This 




Patient and Public Involvement 
Two patient representatives attended a writing group meeting, contributed to the design and 
written content of the PIL and commented on the draft guidelines. The guideline was also reviewed 
by the BASHH Patient and Public Panel.
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Summary of Recommendations  
Section Recommendation Grading 
4.1 Test for M. genitalium infection in all males with non-gonococcal 
urethritis 
1B 
4.1 Test for M. genitalium infection in all individuals with signs and 
symptoms suggestive of pelvic inflammatory disease 
1B 
4.2 Test current sexual partners of persons infected with M. genitalium 1D 
5.2 First void urine is the specimen of choice in males 1C 
5.2 Vaginal swabs (clinician- or self-taken) are the specimen of choice in 
females 
1C 
5.2 All M. genitalium positive specimens should be tested for macrolide 
resistance mediating mutations 
1B 
6.2 Treatment regimens for uncomplicated infection 
1. Doxycycline 100mg two times daily for 7 days followed by 
azithromycin 1g orally as a single dose then 500mg orally once 
daily for 2 days  






6.3 Treatment regimens for complicated infection 
1. Moxifloxacin 400mg orally once daily for 14 days 
 
1D 
6.5 Alternative treatment regimens 
1. Doxycycline 100 mg two times daily for 7 days followed by 
pristinamycin 1g orally four times daily for 10 days   
2. Pristinamycin 1g orally four times daily for 10 days 
3. Doxycycline 100mg orally twice daily for 14 days 








6.11 All patients should attend for a TOC five weeks (and no sooner than three 









Mycoplasma genitalium was first isolated in 1981, having been cultured from urethral specimens of 
two men presenting with non-gonococcal urethritis (NGU)[1]. M. genitalium belongs to the Mollicutes 
class[2],  and with a genome of only 580 kilobases in size,  is the smallest known self-replicating 
bacterium. It lacks a cell wall, and hence is not visible by Gram stain. The organism is fastidious and 
typically requires weeks or months to culture. 
M. genitalium has been detected from genito-urinary, rectal and respiratory tract specimens, but 
carriage in the throat seems to be rare [3]. Although it was initially thought that disease appeared to 
be limited to the genito-urinary tract, there is some evidence it could potentially cause proctitis[3-5].  
The specialised tip-like structure of M. genitalium enables it to adhere to and invade epithelial cells[3]. 
The organism is able to evade the adaptive immune system possibly through both its ability to 
establish intra-cellular infection and by antigenic and phase variation of its surface-exposed proteins, 
and infection may persist for months or years[3, 6, 7].  Although the diseases associated with M. 
genitalium infection are thought largely to be as a result of the host immune response rather than 
organism-specific features, it has been demonstrated in human fallopian tube organ culture that 






2.1 Prevalence in general population and risk factors for infection 
Prevalence estimates for M. genitalium infection in men and women in the general population range 
from 1-2%, being slightly higher in women[9-11]. Similar to C. trachomatis, risk factors for M. 
genitalium infection include younger age, non-white ethnicity, smoking, and increasing number of 
sexual partners[9-11]. However, the prevalence of M. genitalium infection appears to peak later than 
that for C. trachomatis, particularly in men, and to remain higher in older age groups[11-13]. Amongst 
STI clinic attendees, prevalence ranges are higher, from 4-38%[14-16].  
 
2.2 Sexual transmission 
In addition to the sexual behavioural risk factors above, sexual transmission is supported by the 
observation that sexual partners of individuals diagnosed with M. genitalium are more likely to be 
infected than controls[17-19]. Molecular epidemiological studies also support a sexual transmission 
model: in DNA-typing studies, sexual partners who were concurrently infected with M. genitalium 
frequently carry genetically identical strains[20-22].  
Transmission is primarily by genital-genital contact, but M. genitalium has also been detected in the 
ano-rectal compartment [5, 23] and transmission by penile-anal contact has been established[24]. As 
carriage in the oro-pharynx is uncommon, the relative contribution of oral sex is likely to be very small 
[25-27]. The risk of transmission per coital act has yet to be determined but is likely to be less than 
that for chlamydia [27].  
. 
 
2.3 Co-infection with other STIs 
M. genitalium is associated with the detection of other bacterial STIs, C. trachomatis being the most 
frequently isolated co-organism [28-31].  An association between M. genitalium and HIV transmission 
and acquisition is biologically plausible and supported by some studies in sub-Saharan Africa[32-34]. 
 




2.4.1 Non-gonococcal urethritis 
M. genitalium infection is unequivocally and strongly associated with NGU. Typically, the prevalence 
of M. genitalium in men with NGU is 10-20% and in male patients with non-chlamydial non-gonococcal 
urethritis (NCNGU) is 10-35% [3], as compared to 1-2% in the general population[11, 35]. In one meta-
analysis of 19 observational studies examining M. genitalium infection with molecular techniques, 
436/2069 patients with NGU (21.1%) were positive for M. genitalium versus 121/1810 controls (6.7%), 
yielding a pooled odds ratio of 3.8 [95% CI 3.0-4.9][13]. Further systematic reviews have demonstrated 
a similar association, and demonstrated a yet stronger strength of  association with NCNGU[3]. M. 
genitalium is also associated with persistent and recurrent urethritis, where up to 40% of patients may 
have M. genitalium detected[36]. A recent meta-analysis demonstrated an odds ratio of 26 for M. 
genitalium detection in men with persistent urethritis[37].  
 
2.4.2 M. genitalium in the female reproductive tract 
Several studies support an association of M. genitalium infection in cisgender women with post coital 
bleeding and cervicitis, endometritis and pelvic inflammatory disease (PID)[11, 18, 38-41].  
 A recent meta-analysis has demonstrated significant associations between M. genitalium and 
cervicitis (pooled OR 1.66) and PID (pooled OR 2.14), in addition to pre-term birth and spontaneous 
abortion (pooled ORs 1.89 and 1.82 respectively)[42]. M. genitalium is linked aetiologically to PID and 
accounts for 10-13% of cases of PID[43, 44]. It has been shown to ascend from the lower to upper 
female genital tract[3], has been detected frequently from endometrial biopsies in women with PID 
[45] and can cause epithelial cilial damage in human fallopian tube culture. However an association 
with tubal factor infertility has not yet been demonstrated and conducting studies to determine this 
will be difficult[3, 8, 46].  
 
 
2.4.3 Asymptomatic infection 
The evidence suggests that the majority of people infected with M. genitalium in the genital tract do 
not develop disease[27, 47, 48]. Current treatments are imperfect and associated with development 
of antimicrobial resistance[49, 50]. There is no evidence that screening asymptomatic individuals will 
be of benefit, and indeed is likely to do harm at a population level[51]. 
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Current asymptomatic partners (including non-regular partners where there is likely to be further 
sexual contact and risk of reinfection) of individuals with disease caused by M. genitalium infection 
should be tested and/or offered epidemiological treatment (using the same antimicrobial regimen as 





3. Clinical Features  
 
3.1 Signs and symptoms in males[3]:  
  None – the majority are asymptomatic[27] 
Urethral discharge 
 Dysuria 
 Penile irritation  
 
Urethral discomfort  
 
Urethritis (acute, persistent, recurrent) 
 Balanoposthitis (in one study)[52]  
 
3.2 Complications in males 
 Sexually acquired reactive arthritis  
 Epididymitis 
  
The clinical presentation of M. genitalium urethritis is similar to other causes and thus clinical features 
of acute symptomatic NGU cannot be used to determine the infective aetiology[17, 27, 53-56]. 
Although the proportion of infected men that develop symptoms is unknown this is likely to be 
<10%[27].  
Urethral discharge may be present spontaneously or on expression, and urethritis is confirmed by 
demonstrating five or more polymorphonuclear leucocytes (PMNLs) per high power (x1000) 
microscopic field (averaged over five fields with the greatest concentration of PMNLs) on a smear 
obtained from the anterior urethra[57]. 
It is possible that sexually acquired reactive arthritis may occur as a result of M. genitalium infection[3, 
27, 58]. An association with epididymitis is possible, but current data are lacking to support an 
association with prostatitis[3]. M. genitalium has been demonstrated at high prevalence in rectal 
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samples from men who have sex with men (MSM) (particularly HIV-positive MSM), and one study 
suggesting a potential association showed that men with symptoms of proctitis had higher bacterial 
load of M. genitalium than those without rectal symptoms[5, 23]. This warrants further investigation 
with larger studies. 
  
3.3 Signs and symptoms in females 
  Asymptomatic (majority)[18, 40]  
  Dysuria 
  Post-coital bleeding 
Painful inter-menstrual bleeding  
  Cervicitis 
  Lower abdominal pain (see Complications: PID) 
 
3.4 Complications in females 
  Pelvic inflammatory disease 
  Tubal factor infertility (uncertain association) 
  Sexually acquired reactive arthritis 
  Pre-term delivery 
 
Individuals with cervicitis due to M. genitalium frequently have no symptoms at all. If present, 
symptoms are nonspecific, with the most common symptom being post-coital bleeding [59]. Although 
the proportion of infected women that develop symptoms is unknown this is likely to be <5% [47, 48]  
 
Examination is frequently normal, but on speculum examination the presence of mucopurulent 
cervical discharge, cervical friability and elevated numbers of PMNLs on cervical sample Gram staining 
are suggestive of infection[18, 38, 40, 60].  
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Clinical signs and symptoms of M. genitalium-associated PID are similar to, and indistinguishable from, 
PID due to C. trachomatis. 
4. Recommendations for testing 
 
4.1  Based on symptoms 
We recommend testing for M. genitalium infection in people with non-gonococcal urethritis (Grade 
1B) 
We recommend testing for M. genitalium infection in people with signs and symptoms suggestive of 
pelvic inflammatory disease (Grade 1B) 
Consider testing for M. genitalium infection in people with signs or symptoms of muco-purulent 
cervicitis, particularly post-coital bleeding (Grade 2B) 
Consider testing for M. genitalium infection in people with epididymitis (Grade 2D) 
Consider testing for M. genitalium infection in people with sexually-acquired proctitis (Grade 2D) 
 
4.2  Based on risk factors  
We recommend testing current sexual partners of persons infected with M. genitalium (Grade 1D)  
There are currently insufficient data to recommend routine screening for M. genitalium infection in 
asymptomatic individuals 
Asymptomatic individuals with confirmed chlamydia and/or gonorrhoea infection should not be 
routinely tested for M. genitalium. 
 
Whilst the recommendation to test all men with NGU is clear, it is acknowledged that, at the time of 
writing, access to M. genitalium testing is limited and sending all specimens to Public Health England 
for M. genitalium detection and/or determination of resistance status may not be cost viable. Given 
that some men clear M. genitalium with doxycycline treatment alone (for NGU), an alternative 
strategy would be to test men who remain symptomatic following doxycycline and use AMR-guided 
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therapy to treat any positives. However this is not preferable because it would result in a longer 





M. genitalium has fastidious nutritional requirements and is extremely slow growing, therefore 
culture is not appropriate for diagnosis. Nucleic acid amplification tests (NAATs) that detect M. 
genitalium specific DNA or RNA in clinical specimens are the only useful diagnostic method. Several 
CE marked commercial tests are available, although none are currently FDA approved. Careful 
consideration of assay performance based on published data is essential, as the different NAATs are 
likely to have varying performance and lack extensive validation[61]. Local validation is required 
before the implementation of any test. 
It is recommended that all M. genitalium positive specimens should be tested for macrolide resistance 
mediating mutations. Recently, commercial assays detecting macrolide resistance have become 
available. In the absence of local resistance testing, the Public Health England (PHE) Reference 
laboratory offers a molecular macrolide and fluoroquinolone susceptibility genotyping assay for 
specimens positive for M. genitalium. Currently there are no commercial assays available in the UK 
which detect mutations associated with fluoroquinolone resistance although these are likely to be 
available in the near future. 
 
5.1 Specimen collection 
The published data for the optimal specimen type is generally from small studies using a variety of 
different NAATs with different sensitivities, and which lack thorough validation; therefore the 
recommendations are based mainly on a practical approach to specimen collection. 
5.1.1 Men 
First void urine (FVU) is the most sensitive specimen type (sensitivity 98-100%) [13, 61-63]. FVU has 
been shown to be more sensitive than urethral swabs[13, 61, 64]  
There is sparse and conflicting data for meatal swabs; in one study, self-taken penile meatal swabs 
compared with urethral swabs had a sensitivity of 79% for M genitalium, whereas in the same study 
the sensitivity for detection of C. trachomatis was 98%[65]. Another study detected more infections 




Most studies suggest that in women, vulvovaginal swabs are the most sensitive specimen, followed 
by endocervical swabs[61, 67-69]. Using both vaginal and endocervical swabs increases the sensitivity 
further (sensitivity using a PCR assay: vaginal 85.7%, endocervical 74.3%, combined 95.7%)[68] . In one 
study, a quarter of infections would have been missed by only testing one specimen[67]. A recent 
study using a more sensitive assay[61] suggests that a vaginal swab alone is sufficient (sensitivity of 
vaginal swab 100%, endocervical swab 95.6%).  
In the majority of published studies, FVU in cisgender women was found to be less sensitive than 
vaginal or endocervical swabs (FVU sensitivity 58 – 71%)[13, 68, 69] . However a few small studies 
have found no significant difference in the sensitivity between specimen types[62], or FVU to be 
superior to vaginal swabs[64, 70]  
5.2.3 Considerations for transgender men and non-binary assigned female at birth (AFAB) people 
following gender reassignment surgery (GRS) 
There is a paucity of data concerning M. genitalium infection in individuals following GRS. It is 
therefore difficult to recommend an optimal specimen type but this should be guided by sexual history 
and symptoms.  For more detail, clinicians should refer to the forthcoming BASHH standards for trans 
and non-binary people document.  
 
5.2 Recommendations: 
We recommend first void urine as the specimen of choice in cisgender men (1C) 
We recommend vaginal swabs (clinician- or self-taken) as the specimen of choice in cisgender women 
(1C) 
 We recommend that where possible, all M. genitalium-positive specimens should be tested for 
macrolide resistance mediating mutations (1B) 
 
5.3 Window period: 
There are no data on the incubation period for M genitalium, nor on the likely window period before 







6.1 General advice 
Patients should be given a detailed explanation of their condition with particular emphasis on the 
long-term implications for the health of themselves and their partner(s). This should be reinforced 
with clear and accurate written information. A patient information leaflet for Mycoplasma genitalium 
can be found on the guidelines page of the BASHH website.  This will be updated when new guidance 
is published or new information becomes available. 
Patients should be advised to abstain from sexual intercourse until 14 days after the start of 
treatment, and until symptoms have resolved.  Where azithromycin has been used this is especially 
important because of its long half-life and is likely to reduce the risk of selecting/inducing macrolide 
AMR if the patient is re-exposed to  M. genitalium or N. gonorrhoeae. We recommend a test of cure 
(TOC) should be performed in all patients.  
 
6.2 Treatment of uncomplicated urogenital infection (urethritis, cervicitis) 
6.2.1 Eradication rates of M. genitalium following treatment with macrolides are decreasing globally 
and rates of resistance are 30-100%[71]. Macrolide resistance in the UK is estimated at around 40% 
although data are lacking [68]. Reference laboratory data shows higher rates of resistance but is biased 
as isolates tend to come from patients who have previously failed treatment [69].  
 
Despite this M. genitalium still responds to azithromycin in the majority of cases. This has previously 
been given as 500mg single dose followed by 250mg od for 4 days although the evidence that this 
regimen is less likely to select for macrolide resistance than 1g as a single dose is conflicting [27]. More 
recently, data from Australia using a total of 2.5g azithromycin over 4 days showed much lower rates 
of treatment failure in combination with resistance-guided management[72]. Although never 
evaluated, using a 2 g dose over 3 days (1g followed by 500mg for 2 days) may improve microbiological 
cure rates and reduce the risk of macrolide resistance developing in M. genitalium,  whilst being 
tolerable[57].    
 
Knowledge of macrolide resistance status is important in determining whether azithromycin should 
be given but will depend on such testing being available. Even where an organism is known to be 
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initially macrolide-sensitive, an azithromycin-regimen should not be repeated following treatment 
failure because it is likely that resistance has developed on treatment.  
 
6.2.2 Although doxycycline as monotherapy has poor efficacy and eradication rates are low at about 
30-40%, there is evidence that prior treatment with doxycycline may improve treatment success when 
given with, or followed by an extended azithromycin regimen[27, 72]. This is biologically plausible as 
doxycycline reduces the organism load and hence the risk of pre-existing macrolide mutations being 
present. However evidence for this approach is limited, and clinicians should collate and share 
evidence to inform the utility of this practice.  
6.2.3 Moxifloxacin still has excellent efficacy in Europe[54, 73] although resistance is increasing in Asia-
Pacific where its use is greater[74] . Using moxifloxacin first line in all cases of M. genitalium is not 
recommended because future therapeutic options are limited. Regarding optimal duration of therapy, 
a recent meta-analysis reported no significant difference in 7- and 10-day regimens, although more 
treatment failures were seen in the 7-day regimens. Thus, 10 days is preferred[75].  
See Fig. 1 for suggested treatment pathway for men presenting with NGU who subsequently test 




Fig. 1 Suggested treatment pathway for men presenting with non-gonococcal urethritis who 
subsequently test positive for M. genitalium  
MG = Mycoplasma genitalium; Doxycycline 7d = doxycycline 100mg bd for 7 days; Azith 3d – 
azithromycin 1g, then 500mg od for 2 days; Moxifloxacin 10d = moxifloxacin 400mg od for 10 days; 
MRAM = macrolide resistance associated mutation; TOC = test of cure 
*Azithromycin 3d should be started within 2 weeks of finishing doxycycline 
 
6.2.4 Recommended regimens (uncomplicated infections): 
1) Doxycycline 100mgs bd for seven days followed by azithromycin 1g orally as a single dose then 
500mg orally once daily for 2 days* where organism is known to be macrolide-sensitive or 
where resistance status is unknown (1D) 
2) Moxifloxacin 400mg orally once daily for 10 days if organism known to be macrolide-resistant 
or where treatment with azithromycin has failed** (1B) 
3) See alternative regimens 
* Given that most individuals will have had doxycycline as first-line treatment for uncomplicated 
infection, a repeat course is unnecessary once the M. genitalium positive result is known. 
Azithromycin should be given immediately after doxycycline, and ideally within 2 weeks of completing 
doxycycline. If this is not possible, the course of doxycycline should be repeated prior to giving 
azithromycin. 
**Treatment failure is defined as persistent symptoms following treatment, or a positive test of cure 
taken five weeks post-treatment 
 
6.3 Treatment of complicated urogenital infection (PID, epididymo-orchitis) 
6.3.1 There are few studies examining the efficacy of extended azithromycin regimens in the 
treatment of PID and epididymo-orchitis caused by M. genitalium. Data from a recent PID RCT showed 
high rates of macrolide resistance mutations in specimens positive for M. genitalium[76]. Given the 
need for prompt and effective treatment in complex STI syndromes, patients with confirmed M. 
genitalium infection, or who have a partner who has tested positive for M. genitalium should be given 




6.3.2 Recommended regimens (complicated infection): 
1) Moxifloxacin 400mg orally once daily for 14 days (1D) 
 
6.4 Partner notification  
Only current partner(s) (including non-regular partners where there is likely to be further sexual 
contact) should be tested and treated if positive. This is to reduce the risk of re-infection to the index 
patient. Partners should be given the same antibiotic as the index patient unless there is available 
resistance information to suggest otherwise.  
 
6.5 Alternative regimens 
Very little evidence exists for the effectiveness of the following regimens but they may be considered: 
1) Doxycycline 100mgs bd for seven days* then pristinamycin 1g orally four times daily for 
10 days [77] 
2) Pristinamycin 1g orally four times daily for 10 days[77] 
3)    Doxycycline 100mg orally twice daily for 14 days [78, 79] 
4)    Minocycline 100mg orally twice daily for 14 days [80, 81] 
* Prior treatment with doxycycline will reduce M. genitalium load and has been demonstrated to be 
of benefit if administered prior to extended azithromycin and also pristinamycin treatment which is 
only  75% effective as mono-therapy[27]. 
 
6.6 Rectal infection 
This should be managed in the same way as urogenital infection. For severe proctitis, a longer course 
of moxifloxacin (14 days) may be considered. 
 
6.7 Sourcing of unlicensed products 
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Pristinamycin is not currently available in the UK and must be imported against a prescription. The 
cost of importing medicines can be high and availability is inconsistent. An MHRA register of licensed 
wholesalers who can import medicines without a UK Marketing Authorisation is available at: 
https://www.gov.uk/government/publications/human-and-vetinary-medicines-register-of-licensed-
wholesale-distribution-sites-december-2014. At the time of writing, pristinamycin was available from 
several wholesalers with a lead time of two to three weeks. 
6.8 Pregnancy and breastfeeding  
6.8.1 Pregnancy 
Data on M. genitalium and its association with adverse pregnancy outcomes are limited, however it 
has been associated with a small increased risk of preterm delivery and spontaneous abortion [42, 46, 
82, 83]. Azithromycin use during pregnancy is unlikely to increase the risk of birth defects or adverse 
pregnancy outcomes [84-86].  A 3-day course of azithromycin can be used for uncomplicated M. 
genitalium infection detected in pregnancy. The use of moxifloxacin in pregnancy is contra-indicated. 
In women with likely macrolide resistance, or with upper genital tract infection in pregnancy, options 
are limited. [see three references in comment box] Although Doxycycline is considered safe for use in 
the first trimester by the FDA, the BNF advises against its use in the first trimester. 
 
 There are no data regarding the use of pristinamycin in pregnancy. An informed discussion should be 
had with the pregnant woman around the risks associated with the use of these medicines in 
pregnancy and the risks of adverse outcomes associated with M. genitalium infection, and where 
possible treatment should be delayed until after pregnancy. 
 
6.8.2 Breast feeding 
Very low levels of azithromycin are detected in breast milk, and systemic exposure in infants does not 
exceed those observed when that azithromycin is administered for treatment, therefore risk is 
considered to be low[87]. Infants should be monitored for possible side effects due to effects on the 
gastrointestinal flora including diarrhoea and candidiasis. A large cohort study found a significantly 
increased risk of pyloric stenosis in breastfed infants with maternal use of macrolides between 0 to 13 
days of delivery[88] . Doxycycline is excreted into breast milk and is contraindicated in nursing mothers 
due to the risk of tooth discolouration and effects on bone growth. Use of moxifloxacin is contra-
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indicated during breastfeeding. Pristinamycin is contraindicated during breastfeeding due to its side 
effect profile[89].  
 
6.9 Adverse events 
Azithromycin, doxycycline, moxifloxacin and pristinamycin can all cause gastro-intestinal problems 
including nausea but symptoms are most frequently reported with doxycycline and azithromycin 
doses over 1g. Caution should be taken when prescribing azithromycin or moxifloxacin to patients 
already on medications which may prolong the QT interval. The European Medicines Agency (EMA) 
committee has recommended that the use of fluoroquinolone and quinolone antibiotics should be 
restricted following a review of their disabling and potentially long-lasting side effects[90].  Healthcare 
professionals should advise patients to stop treatment with a fluoroquinolone antibiotic at the first 
sign of side effects involving muscles, tendons, bones or the nervous system.  The only absolute 
contra-indication to moxifloxacin is known hypersensitivity to this class of drugs. Hepatotoxicity has 
been reported but is very rare (<1/10 000).  
 
6.10 HIV 
Treatment of M. genitalium in HIV-positive individuals is the same as that for HIV-negative individuals. 
 
 
6.11 Test of Cure and follow up 
TOC is vital in ensuring microbiological clearance of infection and is recommended for all patients with 
confirmed M. genitalium, even if the infection was initially sensitive to macrolides, to detect resistance 
which may have emerged following treatment. Persistence of M. genitalium has been 
demonstrated  in the absence of symptoms in men treated for NGU.[91, 92]  This occurs in about 10-
20% on men treated with doxycycline, but is not associated with development of AMR[27, 92]. 
Persistence of M. genitalium following treatment with azithromycin and moxifloxacin is strongly 
associated with antimicrobial resistance.[91, 92] 
The optimal time to TOC has not been determined, but recent data suggest that very early testing 
after treatment when DNA load is low can give false negative results[93]. Clinical cure (i.e. resolution 
of symptoms) should be established at the TOC visit. The risk of re-infection should be excluded and 
compliance with medication should be verified. 
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We recommend all patients should attend for a TOC five weeks (and no sooner than three weeks in 
order to avoid false negative results) after the start of treatment to ensure microbiological cure and 
to help identify emerging resistance. (1D)  
Treatment failures should be reported to PHE at: https://hivstiwebportal.phe.org.uk 
 
7. Auditable Outcome Measures 
• New cases of M. genitalium should have SHHAPT (Sexual Health and HIV Activity Property 
Type) code “C16” submitted to GUMCAD (performance standard 97%) 
• Individuals treated for M. genitalium should have a TOC at least 5 weeks after the start of 
treatment (performance standard 97%) 
• Cases of confirmed treatment failure by positive TOC should be reported to PHE at: 
https://hivstiwebportal.phe.org.uk 
• Individuals should be provided with written information about their diagnosis and 
management (performance standard 97%) 
• PN should be performed and documented according to the BASHH statement on PN for 
sexually transmissible infections (performance standard 97%) 
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Appendix 1: Example of PICO question used and list of all PICO questions 
What are the optimal specimen types for testing for MG in men and women? 
  INCLUSION EXCLUSION 
Period of 
publication 




• Meta-analysis or 
systematic review  
• Randomised controlled 
trials (RCTs) 
• Non-randomised, prospective 
comparative studies 
• Prospective observational studies 
(e.g. cohort studies) 
• Laboratory studies 
 
• Non-pertinent publication types 
(e.g. expert opinions, letters to 
the editor, editorials (unless 
include original data), 




• Study duration (no minimum) 





• Adults (aged >15 years or above) 
in Europe, N America, Australasia  
• Children (≤15 years) 
• Adults (aged >15 years or above) 









• Inhibitory results 
• Ability to test for other STIs 
concurrently  
  





PICO Questions used 
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1. What is the prevalence of asymptomatic MG in the following populations? 
• Heterosexual men 
• Heterosexual women 
• MSM: HIV-negative 
• MSM: HIV-positive 
• Pregnant women  
 
2. What is the prevalence of symptomatic MG in the following clinical presentations? 
• Non-gonococcal urethritis / non-specific urethritis (first presentation) 
• Non-gonococcal urethritis / non-specific urethritis (persistent and recurrent 
episodes) 
• Muco-purulent cervicitis / intermenstrual bleeding / post-coital bleeding 
• Pelvic inflammatory disease / salpingitis 
• Proctitis 
• Vaginal discharge 
3. What are the clinical features of MG infection 
4. What evidence is there to support testing for MG infection in the populations and clinical 
scenarios examined above? 
5. What are the optimal specimen types for testing for MG in men and women? 
6. What is the incubation/window period for MG detection? 
7. What assays are available for the detection of MG? 
8. What are the rates of microbiological cure/clearance rate/clinical cure/treatment failure for 
each of the following antimicrobial regimens? 
• Azithromycin (all regimens) 
• Moxifloxacin 
• Other quinolones 
• Tetracyclines (inc. doxycycline) 
• Pristinamycin 
• Other macrolides 
9. What are the pharmacological characteristics of the following antimicrobials in the context 
of treatment of MG? 
• Azithromycin (all regimens) 
• Moxifloxacin 
• Other quinolones 
• Tetracyclines (inc. doxycycline) 
• Pristinamycin 
• Other macrolides 
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10. Is a test of cure required, and if so, what is the optimal time to conduct a test-of-cure 
following treatment? 




Appendix 2: NICE Equality Impact Assessment 
Were any potential equality issues with respect to age, disability, gender, race, pregnancy 
and sexual orientation been identified before or during consultation, and, if so what are 
they? 
The guideline is intended for the treatment of individuals aged 16 years and older. Mgen is 
more common in men and women of black ethnicity but this has not influenced the 
recommendations for testing. The patient information leaflet (PIL) is written in English and 
was piloted in English-speaking patients only. No issues were raised with respect to 
disability, gender, pregnancy and sexual orientation. Care has been taken to include the 
correct anatomical site-specific terminology rather than gender terminology for specimen 
taking and there is a separate section for management of Mgen in pregnancy 
 




Is the primary focus of the guideline a population with a specific disability- related 
communication need? 
No 
